Clinical studies have demonstrated that glioblastoma patients with MGMT deficient tumors exhibit longer overall survival following treatment with temozolomide [4], and are more likely to respond to radiotherapy [5], highlighting the potential for personalized cancer therapy based on MGMT status in cancer cells. This evidence concerns the gene MGMT and cancer.